KeraVanta's formulation heritage is supported by third-party ex vivo skin model testing performed using Genoskin's InflammaSkin platform, a psoriasis-like human skin model designed to reproduce key features of Th1/Th17-driven skin inflammation. Nirvanta seed oil formulations were topically applied and evaluated against untreated InflammaSkin controls, a seed oil vehicle, NativeSkin controls, and betamethasone as a positive control. Cytokine release was evaluated at Day 3 and Day 7 using multiplex cytokine analysis, with IL-22 ELISA and histologic review used to confirm model responsiveness and skin integrity.
Study design
Measured signals
Professional interpretation
Observed Testing Highlights
The untreated InflammaSkin model showed strong inflammatory activation, including Th1-associated markers IFN-gamma and TNF-alpha and Th17-associated markers IL-22 and IL-17A. The report observed that the seed oil vehicle reduced several cytokines, including GM-CSF, IFN-gamma, IL-10, and IL-22, suggesting the oil base contributed activity rather than serving as an inert carrier. By Day 7, the study noted targeted modulation associated with active components, including TNF-alpha, IFN-gamma, IL-10, IP-10, MIP-1beta, and IL-17A Gen.B.
What's in Human Skin vs. T-Skin(TM)?
HUMAN SKIN CONTAINS
- Presence of subcutaneous tissue
- Robustness to support injection
- Skin appendages
- Sweat glands
- Sebaceous glands
- Hair follicles
- Peripheral nerves
- Blood circulation
- Melanocytes and melanogenesis
- The presence of functional skin resident immune cells
- Skin barrier Function* Microbiome
Professional positioning: The data are best described as ex vivo cytokine modulation supporting a cosmetic skin-support rationale. Additional donor
testing and human-use studies would be needed to confirm clinical outcomes. This section is written for professional cosmetic/educational review and
should not be interpreted as a clinical efficacy claim or drug claim.

